ArticleFrontiers in pharmacology2025
Synergistic antibacterial photodynamic therapy of lysine-porphyrin conjugate and metal ions combination against
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Photodynamic therapy: A paradigm shift in overcoming drug‑resistant tuberculosis (Review).Molecular medicine reports · 2026Review
- Preparation and biomedical application of light-responsive hydrogels based on natural products.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In previous research, antibacterial photodynamic therapy using lysine-porphyrin conjugate LD Methods: To address this limitation, we developed a synergistic antibacterial strategy by combining LD Results: Synergy was confirmed via minimum inhibitory concentration and fractional inhibitory concentration index analyses, demonstrating 16- to 64-fold enhanced antibacterial efficacy compared to LD Discussion: This study elucidated the enhanced antimicrobial mechanisms and safety of LD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.